SALV Salvarx Group Plc

TIDMSALV

RNS Number : 1025I

SalvaRx Group plc

21 November 2018

SalvaRx Group plc

("SalvaRx", the "Company" or the "Group")

Transaction Update

Further to the announcements of 14 and 28 August 2018 relating to the proposed disposal of the Company's 94.2% interest in SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company is pleased to announce that the Portage shareholder meeting to approve the transaction has been set for 8 January 2019 and meeting materials will be sent to Portage shareholders on the Portage record date, being 23 November 2018. Trading in Portage shares on the Canadian Securities Exchange is expected to resume shortly after the meeting materials have been posted.

The Company will now finalise and publish its shareholder circular and a further announcement will be made by the Company in due course.

Enquiries

 
 SalvaRx Group plc 
 Ian Walters (Chief Executive)                  Tel: +1 203-441-5451 
 Northland Capital Partners Limited             Tel: +44 (0) 20 
  Nominated Adviser and Broker                   3861 6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 Peterhouse Capital Limited                   Tel: +44 (0) 20 
  Joint Broker                                 7469 0932 
  Lucy Williams / Duncan Vasey 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DISPGGGAGUPRGPG

(END) Dow Jones Newswires

November 21, 2018 08:00 ET (13:00 GMT)

Grafico Azioni Salvarx (LSE:SALV)
Storico
Da Feb 2025 a Mar 2025

Grafico Azioni Salvarx (LSE:SALV)
Storico
Da Mar 2024 a Mar 2025